Exchange-traded fund (ETF) inflows reached an astonishing $1 trillion for the first half of 2026 alone, the latest sign that investors everywhere are continuing to lean heavily on these vehicles to simplify their experience and add built-in diversification to their portfolios. Unsurprisingly, the number of funds available continues to skyrocket, although many investors stick with major ETFs tracking the S&P or other prominent indexes instead of venturing into unique strategies.
There's certainly nothing wrong with a low-cost S&P 500 fund, but distinctive strategies have the potential to achieve strong returns with a niche basket of stocks. Although this approach to ETF investing may carry some additional risks as a more speculative play, it nonetheless has paid off for a few funds in particular. The ETFs below, with innovative approaches to biotech clinical trials, buy-now-pay-later programs, and disruptive medicine, respectively, may be worth watching.
